Back to Search
Start Over
Enhanced systemic antitumor efficacy of PD‐1/PD‐L1 blockade with immunological response induced by photodynamic therapy.
- Source :
- Thoracic Cancer; Jun2024, Vol. 15 Issue 18, p1429-1436, 8p
- Publication Year :
- 2024
-
Abstract
- Background: Photodynamic therapy (PDT) is an antitumor therapy and has traditionally been regarded as a localized therapy in itself. However, recent reports have shown that it not only exerts a direct cytotoxic effect on cancer cells but also enhances body's tumor immunity. We hypothesized that the immunological response induced by PDT could potentially enhance the efficacy of programmed death‐1 (PD‐1) / programmed death‐ligand 1 (PD‐L1) blockade. Methods: The cytotoxic effects of PDT on colon 26 cells were investigated in vitro using the WST assay. We investigated whether the antitumor effect of anti‐PD‐1 antibodies could be amplified by the addition of PDT. We performed combination therapy by randomly allocating tumor‐bearing mice to four treatment groups: control, anti‐PD‐1 antibodies, PDT, and a combination of anti‐PD‐1 antibodies and PDT. To analyze the tumor microenvironment after treatment, the tumors were resected and pathologically evaluated. Results: The viability rate of colon 26 cells decreased proportionally with the laser dose. In vivo experiments for combined PDT and anti‐PD‐1 antibody treatment, combination therapy showed an enhanced antitumor effect compared with the control. Immunohistochemical findings of the tumor microenvironment 10 days after PDT indicated that the number of CD8+ cells, the area of Iba‐1+ cells and the area expressing PD‐L1 were significantly higher in tumors treated with combination therapy than in tumors treated with anti‐PD‐1 antibody alone, PDT alone, or the control. Conclusions: PDT increased immune cell infiltration into the tumor microenvironment. The immunological response induced by PDT may enhance the efficacy of PD‐1/PD‐L1 blockade. [ABSTRACT FROM AUTHOR]
- Subjects :
- THERAPEUTIC use of monoclonal antibodies
IN vitro studies
RESEARCH funding
KILLER cells
CHEMICAL reagents
PROGRAMMED death-ligand 1
STATISTICAL sampling
TREATMENT effectiveness
COLON tumors
MICE
IMMUNOHISTOCHEMISTRY
CYTOTOXINS
COMBINED modality therapy
ANIMAL experimentation
PROGRAMMED cell death 1 receptors
DRUG efficacy
PHOTODYNAMIC therapy
CELL survival
IMMUNE checkpoint proteins
IMMUNITY
CHEMICAL inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 17597706
- Volume :
- 15
- Issue :
- 18
- Database :
- Complementary Index
- Journal :
- Thoracic Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 178020492
- Full Text :
- https://doi.org/10.1111/1759-7714.15325